Latest Pyrazines Stories
Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood.
- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - MISSISSAUGA, ON, Aug. 4, 2011 /PRNewswire/ - YM BioSciences Inc.
Smoking cigarettes is a dangerous habit that many are struggling to break, but for the smokers who choose to use one of the most popular smoking cessation drugs on the market, new warnings about the risk of serious cardiovascular events are on their way.
Healthy, middle-aged smokers who take the most popular smoking cessation drug on the market have a 72 percent increased risk of being hospitalized with a heart attack or other serious heart problem.
SOUTH SAN FRANCISCO, Calif., June 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
QUEBEC CITY, April 4 /PRNewswire/ - Aeterna Zentaris Inc.
- totally perplexed and mixed up.